ADNI-Private Partner Scientific Board Update

Robert Dean (Lilly), PPSB Chair

ADNI Steering Committee Meeting
Boston, April 24, 2017
Current PPSB Partners for ADNI3
Benefits of PPSB Partnership

- Membership in the ADNI Private Partner Scientific Board (PPSB)
  - Independent, pre-competitive forum for study-related scientific exchange among partners; convened monthly by the FNIH
  - Receive latest updates on ADNI progress/status
  - Representatives attend annual face-to-face ADNI Steering Committee meeting
  - Chair serves as liaison to ADNI Executive Committee

- Participate in ADNI Core open discussions (Biomarkers, Biostatistics, Clinical, Genetic, Informatics, MRI, Neuropathology, PET, Publications)

- Interact with NIH, FDA, ADNI PI/Core Leaders and industry colleagues

- Participate in industry-initiated Working Groups

- Participate in annual PPSB face-to-face meetings (Spring and Fall)
PPSB Face to Face Meetings

Spring Meeting / 23 April 2017
- ADNI Core Updates
- Readouts on ADNI-related innovation activities
  - DNA Methylation Study (Andy Sakin)
  - Metabolomics & Systems Biology (Rima Kaddurah-Daouk)
  - CSF Biofluid Biomarkers
    - Elecsys Platform (Sandra Rutz)
    - ADNI 1, 2 & GO data output (Les Shaw)
    - Standardization & next steps (Roundtable)

Fall Meeting / Date TBD
- Tentative theme: How PPSB member organizations have utilized ADNI data in trial design
ADNI Cores

Biochemical Biomarker
Les Shaw and John Trojanowski

Biostatistics
Laurel Beckett

Clinical
Ron Petersen & Paul Aisen

Genetics
Andy Saykin

MRI
Cliff Jack

Neuropathology
John Morris

PET
Bill Jagust

Publications
Robert Green

Informatics
Art Toga

RARC
John Hsaio

PPSB Core Liaisons

Susan DeSanti

Jerry Novak

Veronika Logovinsky

Aparna Vasanthakumar

Adam Schwarz

Mark Schmidt

Lee Honigberg

Open

Jerry Novak

PPSB chartered working groups

PET Endpoints WG (2010 – present)
Mark Schmidt, Gregory Klein

Biofluid Biomarkers WG (2012 – present)
Susan DeSanti, Johannes Streffer

Clinical Endpoints WG (2013 – present)
Veronika Logovinsky, Nandini Raghavan

rsfMRI WG (21012 - 2013)
Mark Schmidt, Holly Posner

ADAS-Cog Plus WG (2009 – 2014)
Mark Schmidt, Holly Posner

Aβ as a Biomarker WG (2009 – 2015)
Jeff Waring

Informatics WG (2010 – 2013)
Victor Lobanov

PPSB Chair (transitioning)
Robert Dean (Veronika Logovinsky)

ADNI PI
Mike Weiner

2017
PET Endpoints Working Group

Chair: Mark Schmidt, J&J (Deputy: Gregory Klein, Roche)
- Identify & control sources of PET imaging variability to improve detection of treatment effects
- Potential tau ligand alternatives to AV1451
- Discussion of early frame amyloid imaging for vascular flow (not chartered)

Biofluid Biomarker Working Group

Chair: Susan De Santi, Piramal (Johannes Streffer)
- Access to residual ADNI biological specimens for assay manufacturers
- Efforts to standardize pre-analytical specimen collection & handling - Roundtable discussion (not chartered)
Clinical Endpoints Working Group

Chair: Veronika Logovinsky (Deputy: Nandini Raghavan)

- Four previous workstreams collapsed into one functioning group
- Monitoring implementation and data quality for the Financial Capacity Instrument – Short Form (FCI-SF)
- Monitoring collection of Cog State data
- Finishing a comparison of composite scales developed by different sponsors
- Finalizing manuscripts on earlier work completed by separate workstreams
Coordination and Organization by FNIH

Joseph Menetski, PhD
Deputy Director, Research Partnerships
(301) 594-6596
jmenetski@fnih.org

Dinetta Parrot
Development Officer
(301) 594-2103
dparrot@fnih.org
Back ups
## PPSB: Leadership

<table>
<thead>
<tr>
<th><strong>Chair</strong></th>
<th>Robert Dean, Lilly</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair-elect</strong></td>
<td>Veronika Logovinsky, Eisai</td>
</tr>
<tr>
<td><strong>FNIH</strong></td>
<td>Joseph Menetski, Deputy Director*</td>
</tr>
<tr>
<td></td>
<td>Rosa Canet-Aviles, Scientific Program Manager</td>
</tr>
<tr>
<td></td>
<td>Dinetta Parrott, Partnership Development Officer#</td>
</tr>
<tr>
<td></td>
<td>Meredith Donnelly, Partnership Development Officer</td>
</tr>
<tr>
<td></td>
<td>Eric Barese, Partnership Development Officer</td>
</tr>
<tr>
<td></td>
<td>Julie Wolf-Rodda, Director of Development</td>
</tr>
<tr>
<td><strong>Past PPSB Chairs</strong></td>
<td>Gerald Novak, J&amp;J; Susan De Santi, Piramal; Jesse Cedarbaum, Biogen; Adam Schwarz, Eli Lilly; Johan Luthman, Eisai; Enchi Liu, Prothena; Mark Schmidt, J&amp;J; Holly Soares, BMS; Patricia Cole, Takeda; Eric Siemers, Eli Lilly; Bill Potter, NIMH; Pete Snyder, Lifespan Hospital System</td>
</tr>
<tr>
<td><strong>Core Team</strong></td>
<td>PPSB company / organization primary representatives</td>
</tr>
<tr>
<td><strong>Extended Team</strong></td>
<td>Additional PPSB representatives</td>
</tr>
</tbody>
</table>

*Indicates primary Scientific contact
# Indicates primary Development contact
ADNI-PPSB 2017 Spring F2F Meeting Agenda

REGISTRATION & BREAKFAST

WELCOME
Robert Dean (Lilly), PPSB Chair

Session 1: Progress Update: ADNI Cores

Overview
Mike Weiner (University of California, San Francisco)

Clinical Core
Paul Aisen (University of Southern California)

PET Core
Susan Landau (University of California, Berkeley)

MRI Core
Clifford Jack (Mayo Clinic)

BREAK

Biostatistics Core
Laurel Beckett (University of California, Davis)

Bioinformatics Core
Arthur Toga (University of Southern California)

Data and Publications Committee
Robert Green (Harvard Medical School)

LUNCH

Session 2: Progress Update - Genetics

ADNI DNA Methylation Study
Andy Saykin (Indiana University) and Aparna Vasanthakumar (AbbVie)

ADNI Metabolomics Studies
Rima Kaddurah-Daouk (Duke University) and Kwangsik Nho (Indiana University)

Additional Core Update

Neuropathology Core
John Morris (Washington University)

BREAK

Session 3: Progress Update – Biofluid Biomarkers

Roche Elecsys Background
Sandra Rutz (Roche Diagnostics)
Roche Elecsys Analysis
Les Shaw (UPenn)

Session 4: Roundtable discussion

Towards a Standardization of Fluid Biomarkers – Next Steps
Richard Batria-Utermann(Roche Diagnostics), Miguel Mendoza(Roche Diagnostics),
Zivjena Vucetic (FujiRebio), John Lawson(FujiRebio), Alvysdas Mikulskis (Biogen), Mary
Savage (Merck), Leslie Shaw (University of Pennsylvania), Britta Brix (EUROIMMUN)

Closing comments
Robert Dean (Lilly), PPSB Chair
Mike Weiner (University of California, San Francisco)

ADJOURN